CMS investigating ‘patient dumping’ at U of Maryland hospital

A viral video showing a confused patient wearing only a hospital gown being left at a bus stop outside the University of Maryland Medical Center has prompted a CMS investigation into whether the facility violated any federal regulations.

According to NPR, CMS initiated the probe after seeing the media coverage of the incident. While it didn’t cite a specific regulation or law which may be violated, one possibility is the hospital went against the Emergency Medical Treatment and Labor Act (EMTALA), which could result in it losing Medicare or Medicaid status.

"If you get the federal government involved and they're looking into your actions and nonactions, it's a big deal, practically and symbolically," said Frankie Berger, the director of advocacy at the Treatment Advocacy Center.

While the hospital has apologized for how the patient, later identified as Rebecca, was treated, her family has said it's exploring legal action over the incident. Her mother, Cheryl Chandler, said her daughter is mentally ill, but is not homeless and has health insurance.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.